Home > Quotes > SRPT > Press Releases
SRPT

Sarepta Therapeutics, Inc. Press Releases

$36.65
*  
0.48
  negative  
1.29%
Get SRPT Alerts
*Delayed - data as of May 21, 2013 
Exchange: NASDAQ
Industry: Consumer Durables
Community Rating:
 
 

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 | Sponsored
Viewing
Filtered By
Ordered By

Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
05/10/2013 8:30AM - Market Wire

Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments
05/09/2013 7:00AM - Market Wire

Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus
05/07/2013 8:30AM - Market Wire

Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013
04/26/2013 4:05PM - Market Wire

Sarepta Therapeutics to Present Company Overview at the Needham Annual Healthcare Conference
04/18/2013 4:05PM - Market Wire

Sarepta Therapeutics Announces FDA Will Consider Accelerated Approval for Eteplirsen After Further Review of Data on Dystrophin and Clinical Outcomes
04/15/2013 4:10PM - Market Wire

Sarepta Therapeutics and University of Western Australia Announce Exclusive Worldwide Licensing Agreement for Exon-Skipping Program in Duchenne Muscular Dystrophy
04/11/2013 8:30AM - Market Wire

Over $400 Million Raised by U.S. Life Sciences Companies Through At-the-Market (ATM) Offerings in 2012, Reports Brinson Patrick
04/08/2013 8:00AM - PR Newswire

Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy
04/05/2013 8:30AM - Market Wire

Emerging Growth Equities, Ltd. Initiates Coverage of Sarepta Therapeutics, Inc. (SRPT) With a BUY Rating and $38.00 Price Target
03/11/2013 1:17PM - PR Newswire

Drug Approvals, Breakthrough Treatments and Royalties - Research Report on Celgene Corporation, Onyx Pharmaceuticals, Sarepta Therapeutics, VIVUS and Achillion Pharmaceuticals
03/08/2013 8:00AM - PR Newswire

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2012 Financial Results and Recent Corporate Developments
03/07/2013 7:00AM - Market Wire

Sarepta's Marburg Drug Shows High Survival Rates After Intramuscular Delivery in Non-Human Primates
03/04/2013 8:30AM - Market Wire